GA-TSYS
12.9.2019 14:02:03 CEST | Business Wire | Press release
TSYS (NYSE: TSS) today announced a new authentication product that provides unprecedented real-time verification of customer identities. The new offering, the TSYS Authentication PlatformSM , relies on customer experience data collected from direct cardholder touchpoints and integrates into TSYS clients’ existing authentication systems. TSYS Authentication Platform is available in Europe and will be launched in North America in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005131/en/
The new product is designed to verify that a person is who he or she claims to be, reducing application, transaction and account takeover fraud, while still providing a frictionless customer experience. It’s effective at combatting synthetic identity fraud because it does not rely on reported data, which inherently creates inefficient lag time in the verification process.
The platform utilizes the latest technology – including machine learning – to provide real-time, informed opinions about any type of remote customer interaction or transaction with a financial institution for both consumer and commercial relationships. Examples include originating an account, updating a customer profile, changing a password or making a purchase.
TSYS can provide unparalleled cross-issuer and cross-border insight thanks to its relationships with more than 130 card issuers worldwide.
“At TSYS, we understand how various transactions are connected because we work with a global network of card issuers representing millions of individual accounts,” said Justin Griggs, senior vice president of product strategy and commercialization, TSYS Issuer Solutions. “If a device has been compromised in Ireland, for example, we can use that information to flag a remote login attempt in North America. We have real-time knowledge of potential fraud issues, and now we’re using that information to help our clients authenticate their customers and transactions across any use case.”
The TSYS Authentication Platform aids TSYS customers with their compliance needs to align with the European Union’s Payment Service Directive 2 (PSD2) and Strong Customer Authentication (SCA) provision by providing the ability to flexibly keep pace with the rapidly evolving world of authentication.
TSYS partnered with four key companies to develop the product:
- Featurespace , the leading provider of the award-wining, scalable ARIC™ platform and inventor of Adaptive Behavioral Analytics, previously collaborated with TSYS on the TSYS Foresight Score SM transaction fraud product. The new Authentication Platform utilizes Featurespace’s flexible multi-tenant capabilities that enables an industry-wide view of new fraud vectors for advanced decisioning.
- Emailage is a global leader in online fraud prevention and email risk assessment. Emailage’s technology leverages email address metadata, state of the art machine learning and dynamic data from a global network to generate multi-dimensional identity profiles and render a fraud risk score. This helps users build better informed fraud decision making processes.
- InAuth is a leading digital device intelligence company that specializes in using browser and app information to authenticate online transactions. It will ensure that TSYS clients know and understand the trustworthiness of every device interacting with their digital channels, including mobile app, mobile web and desktop.
- Payfone is the leading digital identity authentication network for the connected world. Their solutions enable consumers and businesses to transact with trust across all channels. Payfone can improve “pass rates” while thwarting synthetic IDs and identity theft with real-time, passive authentication and predictive identity confidence through their proprietary Trust Score™. They will measure the potential risk associated with a digital identity, so users can trust they know who their customers are.
TSYS will continue to enhance its authentication measures to help combat the fraud landscape and expects to leverage additional functionality such as facial recognition, document scanning, and behavioral biometrics, as well as utilize differentiated data sets through 2020 and beyond.
For more information about the TSYS Authentication Platform visit https://www.tsys.com/authentication-platform
About TSYS
TSYS® (NYSE: TSS) is a leading global payments provider, offering seamless, secure and innovative solutions across the payments spectrum — for issuers, merchants and consumers. We succeed because we put people and their needs at the heart of every decision to help them unlock payment opportunities. It’s an approach we call People-Centered Payments® .
Our headquarters are located in Columbus, Ga., U.S.A., with approximately 13,000 team members and local offices across 13 countries. TSYS generated revenue of $4.0 billion in 2018, while processing more than 32.3 billion transactions. We are a member of The Civic 50 and were named one of the 2018 World's Most Ethical Companies by Ethisphere magazine. TSYS is a member of the S&P 500 and routinely posts all important information on its website. For more, visit tsys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
